ReviewDrugs in context2020
Conjunctivitis in patients with atopic dermatitis treated with dupilumab.
Review in Drugs in context, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.The Australasian journal of dermatology · 2022Pooled it
- Early Ocular-Surface Changes During Dupilumab Treatment According to Hyaluronic Acid Use: A Prospective Cohort Study.Journal of personalized medicine · 2026Article
- Dupilumab-Related Ocular Surface Disease in Atopic Dermatitis: Risk Stratification, Monitoring, and Persistence-Preserving Management.Journal of clinical medicine · 2026Review
- Hypereosinophilia With Organ Damage Secondary to Dupilumab Therapy: A Case Report and Literature Review.Case reports in dermatological medicine · 2026Article
- A monocentric retrospective real-world study from North Poland of dupilumab in adults and paediatric patients with atopic dermatitis: efficacy, safety, and dupilumab-associated hypereosinophilia.Postepy dermatologii i alergologii · 2026Article
- Clinical efficacy of Dupilumab in the treatment of moderate to severe Atopic Dermatitis and Type-II Inflammation-Related comorbidities: A real-world study.Pakistan journal of medical sciences · 2025Article
- Ocular Side Effects of Dupilumab: A Comprehensive Overview of the Literature.Journal of clinical medicine · 2025Review
- Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy.Dermatology and therapy · 2025Review
- Targeting the IL-4/IL-4R Axis in Th2 Inflammatory Diseases: A Review of Clinical Efficacy and Safety.Journal of inflammation research · 2025Review
- Possible viral agents to consider in the differential diagnosis of blepharoconjunctivitis.World journal of virology · 2024Article
- Review
- IL-13 inhibition in the treatment of atopic dermatitis - new and emerging biologic agents.The Journal of international medical research · 2024Review
- Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience.Postepy dermatologii i alergologii · 2023Article
- The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2023Article
- Targeting Interleukin 13 for the Treatment of Atopic Dermatitis.Pharmaceutics · 2023Review
- Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.Journal of clinical pharmacology · 2022Article
- A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis.JID innovations : skin science from molecules to population health · 2021Review
- Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase.Scientific reports · 2021Article
- Case Report: Dupilumab Successfully Controls Severe Eczema in a Child With Elevated IgE Levels and Recurrent Skin Infections.Frontiers in pediatrics · 2021Article
- Selective IL-13 inhibitors for the treatment of atopic dermatitis.Drugs in context · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL-13 are key cytokines in the immunopathogenesis of AD. New emerging agents include dupilumab, a fully human monoclonal antibody directed against the IL-4 receptor a subunit that blocks both IL-4 and IL-13 signaling and has shown significant efficacy in patients with moderate-to-severe AD. Dupilumab is approved for the treatment of moderate-to-severe AD, moderate-to-severe eosinophilic or oral corticosteroid-dependent asthma, and chronic rhinosinusitis with nasal polyps. Data from phase phase 2 and 3 studies have revealed that dupilumab generally has a low rate of adverse events, although an increased incidence of mild-to-moderate conjunctivitis has been reported for dupilumab compared with placebo. The present paper reviews the data of dupilumab-associated conjunctivitis and risk factors in adults with moderate-to-severe AD and other atopic diseases in dupilumab clinical trials and addresses the characteristics and treatment options available for this clinically highly relevant condition. Additionally, it presents data from ten studies in the real-life setting with dupilumab. Dupilumab-associated conjunctivitis incidence is higher in AD, although most cases are mild-to-moderate and have good response to topical treatment, with no need to suspend dupilumab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.